Amyloid Cardiomyopathy

Cardiovascular
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
1
AG10Phase 21 trial
Active Trials
NCT03536767Active Not Recruiting55Est. Jul 2027
Pfizer
PfizerNEW YORK, NY
1 program
Amyloid CardiomyopathyN/A1 trial
Active Trials
NCT04738266Unknown381Est. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BridgeBio PharmaAG10
PfizerAmyloid Cardiomyopathy

Clinical Trials (2)

Total enrollment: 436 patients across 2 trials

Open-Label Study of AG10 in Patients with Cardiomyopathy

Start: Aug 2018Est. completion: Jul 202755 patients
Phase 2Active Not Recruiting
NCT04738266PfizerAmyloid Cardiomyopathy

Unmasking the Prevalence of AC in an Unselected Echocardiographic Population

Start: Nov 2020Est. completion: Jul 2021381 patients
N/AUnknown

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space